Chemistry, Manufacturing, and Controls (CMC)
|
Analytical Procedures and Methods Validation (PDF - 91KB)
|
Draft Guidance
|
08/30/00
|
Chemistry, Manufacturing, and Controls (CMC)
|
Assay Development for Immunogenicity Testing of Therapeutic Proteins (PDF - 161KB)
|
Draft Guidance
|
12/04/09
|
Chemistry, Manufacturing, and Controls (CMC)
|
Botanical Drug Products (PDF - 437KB)
|
Final Guidance
|
06/01/04
|
Chemistry, Manufacturing, and Controls (CMC)
|
Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products (PDF - 33KB)
|
Final Guidance
|
07/01/97
|
Chemistry, Manufacturing, and Controls (CMC); Modernization Act
|
Changes to an Approved NDA or ANDA (PDF - 173KB)
|
Final Guidance
|
04/01/04
|
Chemistry, Manufacturing, and Controls (CMC)
|
Changes to an Approved NDA or ANDA: Questions and Answers (PDF - 35KB)
|
Final Guidance
|
01/01/01
|
Chemistry, Manufacturing, and Controls (CMC)
|
Changes to an Approved NDA or ANDA; Specifications – Use of Enforcement Discretion for Compendial Changes (PDF - 24KB)
|
Final Guidance
|
11/19/04
|
Chemistry, Manufacturing, and Controls (CMC)
|
CMC Postapproval Manufacturing Changes Reportable in Annual Reports (PDF - 78KB)
|
Draft Guidance
|
06/24/10
|
Chemistry, Manufacturing, and Controls (CMC)
|
Comparability Protocols -- Chemistry, Manufacturing, and Controls Information (PDF - 195KB)
|
Draft Guidance
|
02/25/03
|
Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products
|
Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products
|
|
02/01/08
|
Chemistry, Manufacturing, and Controls (CMC)
|
Container Closure Systems for Packaging Human Drugs and Biologics (PDF - 164KB)
|
Final Guidance
|
05/01/99
|
Chemistry, Manufacturing, and Controls (CMC)
|
Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers (PDF - 34KB)
|
Final Guidance
|
05/01/02
|
Chemistry, Manufacturing, and Controls (CMC)
|
Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products
|
Final Guidance
|
04/01/96
|
Chemistry, Manufacturing, and Controls (CMC)
|
Development of New Stereoisomeric Drugs
|
Final Guidance
|
05/01/92
|
|
Drug Master Files: Guidelines
|
|
|
Chemistry, Manufacturing and Controls (CMC)
|
Drug Master Files (DMFs)
|
Additional Information regarding DMF's
|
|
Chemistry, Manufacturing, and Controls (CMC)
|
Drug Master Files for Bulk Antibiotic Drug Substances (PDF - 23KB)
|
Final Guidance
|
11/01/99
|
Chemistry, Manufacturing, and Controls (CMC)
|
Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals (PDF - 88KB)
|
Draft Guidance
|
09/11/02
|
Chemistry, Manufacturing, and Controls (CMC)
|
Environmental Assessment of Human Drug and Biologics Applications (PDF - 188KB)
|
Final Guidance
|
07/01/98
|
Chemistry, Manufacturing, and Controls (CMC)
|
Format and Content for the CMC Section of an Annual Report (PDF - 29KB)
|
Final Guidance
|
09/01/94
|
Chemistry, Manufacturing, and Controls (CMC)
|
Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting (PDF - 74KB)
|
Final Guidance
|
10/11/11
|
Chemistry, Manufacturing, and Controls (CMC)
|
INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information (PDF - 283KB)
|
Final Guidance
|
05/20/03
|
Chemistry, Manufacturing, and Controls (CMC)
|
IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information (PDF - 30KB)
|
Final Guidance
|
05/01/01
|
|
Guidance for Industry: Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations (PDF - 26KB)
|
|
|
Chemistry, Manufacturing and Controls (CMC)
|
Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products (PDF - 60KB)
|
Draft Guidance
|
03/01/12
|
Chemistry, Manufacturing, and Controls (CMC)
|
Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation (PDF - 146KB)
|
Draft Guidance
|
08/21/02
|
Chemistry, Manufacturing, and Controls (CMC)
|
Monoclonal Antibodies Used as Reagents in Drug Manufacturing (PDF - 29KB)
|
Final Guidance
|
03/01/01
|
Chemistry, Manufacturing, and Controls (CMC)
|
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products (PDF - 361KB)
|
Draft Guidance
|
11/19/98
|
Chemistry, Manufacturing, and Controls (CMC)
|
Nasal Spray and Inhalation Solution, Suspension, and Drug Products (PDF - 285KB)
|
Final Guidance
|
07/01/02
|
Chemistry, Manufacturing, and Controls (CMC)
|
NDAs: Impurities in Drug Substances (PDF - 11KB)
|
Final Guidance
|
02/01/00
|
Chemistry, Manufacturing, and Controls (CMC)
|
Orally Disintegrating Tablets (PDF - 52KB)
|
Final Guidance
|
12/17/08
|
Chemistry, Manufacturing, and Controls (CMC)
|
PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites (PDF - 76KB)
|
Final Guidance
|
04/28/98
|
Chemisty; Manufacturing and Controls (CMC)
|
Regulatory Classification of Pharmaceutical Co-Crystals (PDF - 97KB)
|
Draft Guidance
|
12/01/11
|
Chemistry, Manufacturing, and Controls (CMC)
|
Residual Drug in Transdermal and Related Drug Delivery Systems (PDF - 44KB)
|
Final Guidance
|
08/16/11
|
Chemistry, Manufacturing, and Controls (CMC)
|
Residual Solvents in Drug Products Marketed in the United States (PDF - 52KB)
|
Final Guidance
|
11/24/09
|
Chemistry, Manufacturing, and Controls (CMC)
|
Reviewer Guidance, Validation of Chromatographic Methods (PDF - 703KB)
|
Final Guidance
|
11/01/94
|
Chemistry, Manufacturing, and Controls (CMC)
|
Size of Beads in Drug Products Labeled for Sprinkle. (PDF - 148KB)
|
Final Guidance
Note: Corrected a non-substantive error on p. 2 of guidance
|
05/02/12
|
Chemistry, Manufacturing, and Controls (CMC)
|
Submitting Documentation for the Manufacturing of and Controls for Drug Products (PDF - 1MB)
|
Final Guidance
|
02/01/87
|
Chemistry, Manufacturing, and Controls (CMC)
|
Guidelines for Submitting Samples and Analytical Data for Methods Validation
|
Final Guidance
|
02/01/87
|
Chemistry, Manufacturing, and Controls (CMC)
|
Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances (PDF - 94KB)
|
Final Guidance
|
02/01/87
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (PDF - 60KB)
|
Final Guidance
|
11/01/95
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-IR Questions and Answers about SUPAC-IR Guidance
|
Final Guidance
|
02/18/97
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms Manufacturing Equipment Addendum (PDF - 117KB)
|
Final Guidance
|
01/01/99
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (PDF - 215KB)
|
Final Guidance
|
10/06/97
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-SS: Nonsterile Semisolid Dosage Forms Manufacturing Equipment Addendum (PDF - 61KB)
|
Draft Guidance
|
12/01/98
|
Chemistry, Manufacturing, and Controls (CMC)
|
SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation (PDF - 118KB)
|
Final Guidance
|
05/01/97
|
Guidance for Industry - The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use
|
The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use
|
|
09/01/97
|
Chemistry, Manufacturing, and Controls (CMC)
|
Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation (PDF - 99KB)
|
Draft Guidance
|
08/29/11
|